Acute Hereditary C1 Inhibitor Deficiency When On-Demand Therapy Is Unavailable

This protocol addresses acute attack management of hereditary C1 inhibitor deficiency in the specific situation where standard on-demand treatments are not accessible. It outlines a structured last-resort approach aimed at patient safety during an acute episode.

Clinical scenario: Acute hereditary C1 inhibitor deficiency presenting when preferred FDA-approved on-demand therapies are unavailable, requiring consideration of alternative acute interventions and supportive measures.

Treatment approach (partial overview only): The protocol specifies an intravenous last-resort therapy to be administered with defined airway precautions, alongside supportive measures selected according to episode severity. The full structured regimen — including sequencing, specific indications, safety criteria, and step-by-step clinical decision points — is available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jaip.2020.08.046

Fresh frozen plasma (FFP) contains C1INH and can be used to treat HAE attacks if none of the FDA-approved on-demand medications are available.

If another acute therapy is not available, FFP remains an option as long as precautions are taken to protect the patient's airway (particularly if oropharyngeal or laryngeal swelling is present).

In the absence of effective on-demand treatment, patients may require supportive care (ie, IV fluids, antiemetics, narcotic pain medication, or intubation).

View source ↗